ScvO2-Centered Optimisation of RED Blood Cell Transfusions (NCT07509203) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
ScvO2-Centered Optimisation of RED Blood Cell Transfusions
Hungary600 participantsStarted 2026-04-15
Plain-language summary
This clinical trial aims to personalise red blood cell transfusion strategies in the crtitically ill patients. The amount of transfusions needs to be minimised in order to prevent adverse events and organ dysfunctions linked to high amounts of red blood cell transfusions.
The researchers aim to investigate the efficacy and safety of measuring the central venous oxygen saturation (ScvO2) (oxygen content in a venous blood sample taken from a central line) to guide clinicians if transfusion is necessary.
The researchers aim to compare the ScvO2 guided transfusion strategy with transfusion based on the clinician's judgment (taking into consideration the patients' comorbidities and actual vital parameters).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient in medical/surgical/trauma ICU
* Hemoglobin level between 7g/dl and 9g/dl
* Written informed consent by patient or next of kin
* Hemodynamically stable:
* CRT normal
* Serum lactate \<2 mmol/l
* MAP \>65 mmHg
* noradrenalin \< 0,2 mcg/kg/min and no increase in 6 hours
* No new ischemic change on ECG
* Monitored with CVC, arterial catheter, hourly urine output
* Respiratorily stable
* No support or
* Nasal canula/face mask O2 supplementation or
* NIV or
* Invasive mechanical ventillation: PC/VC/PS, PEEP\< 15 cmH2O FiO2 \< 50% and no increase in 6 hours
* PiCCO or expert ECHO available within 48hours
Exclusion Criteria:
* ScvO2\>80%
* Acid-base imbalance (pH\<7.3 or pH\>7.5)
* Chronic kidney disease (KDIGO Stage 3-4-5)
* Acute heart failure (ESC 2021 definition)
* Pregnancy
* Active bleeding
* Neurotrauma requiring intracranial pressure monitoring
* Morbid obesity BMI \>40
* Horowitz Quotient (paO2/FiO2) \< 200
* Acute and chronic liver failure (Child-Pugh B,C)
* Fever
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of units of red blood cells transfused per patient
Timeframe: From enrollment to the discharge from the intensive care unit or date of death on the intensive care unit, whichever came first, assessed up to 6 months